

Fernando Cabanillas

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2028711/fernando-cabanillas-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

189
papers

10,899
citations

46
h-index

101
g-index

191
ext. papers

11,607
ext. citations

3.5
avg, IF

5.12
L-index

#	Paper	IF	Citations
189	Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1244	2.2	2910
188	Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2453-63	2.2	936
187	Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 667-75	2.2	465
186	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. <i>Cancer</i> , 2006 , 106, 1569-80	6.4	441
185	Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. <i>Lancet Oncology, The</i> , 2012 , 13, 716-23	21.7	227
184	Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. <i>Cancer</i> , 2003 , 97, 586-91	6.4	202
183	Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. <i>Blood</i> , 2004 , 104, 1624-30	2.2	202
182	Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1582-9	2.2	175
181	Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010 , 150, 200-8	4.5	168
180	Long-term results with radiotherapy for Stage I-II follicular lymphomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 51, 1219-27	4	131
179	The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas. <i>Blood</i> , 1998 , 91, 2955-2960		126
178	Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. <i>Cancer</i> , 1997 , 80, 477-88	6.4	116
177	Correlation of Bcl-2 Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma. <i>Blood</i> , 1999 , 93, 3081-3087	2.2	114
176	Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. <i>British Journal of Haematology</i> , 1997 , 99, 618-24	4.5	112
175	Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. <i>Blood</i> , 2001 , 98, 2784-90	2.2	110
174	Novel 5' exonuclease-based real-time PCR assay for the detection of t(14;18)(q32;q21) in patients with follicular lymphoma. <i>American Journal of Pathology</i> , 1998 , 153, 63-8	5.8	107
173	Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992 , 23, 407-12	4	107

172	Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2115-22	2.2	106
171	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 996-1000	6.4	105
170	Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. <i>Cancer</i> , 1980 , 46, 2356-9	6.4	94
169	Primary ovarian non-Hodgkin's lymphoma: outcome after treatment with combination chemotherapy. <i>Gynecologic Oncology</i> , 1997 , 64, 446-50	4.9	90
168	Stage I-II follicular lymphoma. Treatment results for 76 patients. <i>Cancer</i> , 1986 , 58, 1596-602	6.4	90
167	Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. <i>American Journal of Pathology</i> , 2001 , 159, 527-35	5.8	84
166	Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial. <i>Cancer</i> , 1985 , 56, 1305-10	6.4	83
165	Localized primary malignant lymphoma of bone. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997 , 37, 1087-93	4	81
164	BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. <i>Blood</i> , 2002 , 100, 3935-41	2.2	81
163	Mantle-cell lymphoma. <i>Lancet Oncology, The</i> , 2001 , 2, 141-8	21.7	80
162	Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. <i>Cancer</i> , 2006 , 106, 120-7	6.4	73
161	Localized primary non-Hodgkin lymphoma of the breast. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998 , 21, 376-80	2.7	69
160	Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. <i>British Journal of Haematology</i> , 2016 , 172, 80-8	4.5	67
159	Fine-needle aspiration cytology of peripheral T-cell lymphoma. A cytologic, immunologic, and cytometric study. <i>American Journal of Clinical Pathology</i> , 1989 , 91, 120-31	1.9	64
158	Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. <i>American Journal of Medicine</i> , 1989 , 87, 167-72	2.4	63
157	T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease. <i>American Journal of Surgical Pathology</i> , 1996 , 20, 193-201	6.7	62
156	9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1986 , 18, 145-52	3.5	61
155	European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. <i>Cancer</i> , 2002 , 94, 1731-8	6.4	59

154	Accuracy of diagnosis of malignant lymphoma by combining fine-needle aspiration cytomorphology with immunocytochemistry and in selected cases, Southern blotting of aspirated cells: a tissue-controlled study of 86 patients. <i>Diagnostic Cytopathology</i> , 1992 , 8, 456-64	1.4	59
153	Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections. <i>American Journal of Clinical Pathology</i> , 2002 , 118, 328-34	1.9	58
152	CD30 ligand is expressed on resting normal and malignant human B lymphocytes. <i>British Journal of Haematology</i> , 1996 , 93, 569-71	4.5	58
151	Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. <i>American Journal of Medicine</i> , 1988 , 84, 581-9	2.4	58
150	Factors Predicting for Response and Survival in Adults With Advanced Non-Hodgkin's Lymphoma. <i>Archives of Internal Medicine</i> , 1978 , 138, 413		58
149	Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. <i>Leukemia and Lymphoma</i> , 2000 , 39, 77-85	1.9	56
148	Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. <i>Blood</i> , 2002 , 100, 4351-7	2.2	54
147	Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. <i>Cancer Journal (Sudbury, Mass)</i> , 2002 , 8, 377-83	2.2	53
146	COINCIDENT RENAL CELL CARCINOMA AND NONHODGKIN'S LYMPHOMA: THE M.D. ANDERSON EXPERIENCE AND REVIEW OF THE LITERATURE. <i>Journal of Urology</i> , 1998 , 159, 714-717	2.5	52
145	Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. <i>American Journal of Medicine</i> , 1983 , 74, 382-8	2.4	52
144	Hodgkin's disease variant of Richter's syndrome: experience at a single institution. <i>Leukemia and Lymphoma</i> , 1996 , 23, 333-7	1.9	49
143	Beta-lactam regimens for the febrile neutropenic patient. <i>Cancer</i> , 1990 , 65, 9-16	6.4	46
142	The role of mitoxantrone in the treatment of indolent lymphomas. <i>Oncologist</i> , 2005 , 10, 150-9	5.7	45
141	Chemotherapy as definitive treatment of stage I-II large cell and diffuse mixed lymphomas. <i>Hematological Oncology</i> , 1985 , 3, 25-31	1.3	45
140	Chromosomal abnormalities in adult non-endemic Burkitt's lymphoma and leukemia: 22 new reports and a review of 148 cases from the literature. <i>Hematological Oncology</i> , 1991 , 9, 63-78	1.3	43
139	Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. <i>Hematology/Oncology Clinics of North America</i> , 1997 , 11, 937-47	3.1	42
138	Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. <i>British Journal of Haematology</i> , 1998 , 103, 270-5	4.5	42
137	International prognostic index-based outcomes for diffuse large B-cell lymphomas. <i>Cancer</i> , 2002 , 94, 3083-8	6.4	42

136	Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization. A useful ancillary method for the diagnosis of mantle cell lymphoma. <i>American Journal of Clinical Pathology</i> , 2000 , 114, 248-57	1.9	42
135	Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995 , 31, 3-11	4	41
134	Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type. <i>Cancer</i> , 1986 , 57, 971-7	6.4	41
133	High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. <i>Leukemia and Lymphoma</i> , 1998 , 30, 563-71	1.9	39
132	Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance. <i>Cancer</i> , 2002 , 94, 1-5	6.4	38
131	Protected environment-prophylactic antibiotic program for malignant lymphoma. Randomized trial during chemotherapy to induce remission. <i>American Journal of Medicine</i> , 1979 , 66, 74-81	2.4	38
130	Marginal zone lymphomas: factors that affect the final outcome. <i>Cancer</i> , 2010 , 116, 4291-8	6.4	37
129	Nodular malignant lymphomas: factors affecting complete response rate and survival. <i>Cancer</i> , 1979 , 44, 1983-9	6.4	37
128	Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. <i>European Journal of Haematology</i> , 2006 , 77, 387-94	3.8	35
127	Surgical debulking is associated with improved survival in stage I-II diffuse large cell lymphoma. <i>Cancer</i> , 1990 , 66, 267-72	6.4	35
126	Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2085-92	1.9	34
125	Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. <i>British Journal of Haematology</i> , 1997 , 96, 328-32	4.5	33
124	Epigenetic therapy of lymphoma using histone deacetylase inhibitors. <i>Clinical and Translational Oncology</i> , 2010 , 12, 401-9	3.6	32
123	An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. <i>Cancer</i> , 2002 , 95, 2534-8	6.4	32
122	Nephrotoxicity of Combined Cephalothin-Gentamicin Regimen. <i>Archives of Internal Medicine</i> , 1975 , 135, 850		31
121	Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997 , 39, 609-16	4	30
120	Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. <i>Cancer</i> , 2008 , 113, 2734-41	6.4	29
119	High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1986 , 22, 871-7		29

118	Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 55, 36-43	4	28
117	Thalidomide for patients with recurrent lymphoma. <i>Cancer</i> , 2004 , 100, 1186-9	6.4	27
116	Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation. <i>Leukemia and Lymphoma</i> , 1998 , 30, 367-79	1.9	26
115	Outcome of Hodgkin's disease in elderly patients. <i>Hematological Oncology</i> , 1995 , 13, 19-27	1.3	25
114	Primary parotid lymphoma: the effect of International Prognostic Index on outcome. <i>Leukemia and Lymphoma</i> , 1997 , 26, 49-56	1.9	24
113	Primary effusion lymphoma in an HIV-negative patient with no serologic evidence of Kaposi's sarcoma virus. <i>Leukemia and Lymphoma</i> , 2001 , 41, 185-9	1.9	24
112	The expanding role of fludarabine in hematologic malignancies. <i>Leukemia and Lymphoma</i> , 1994 , 14 Suppl 2, 11-6	1.9	24
111	Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 783-796	2	23
110	Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 73-80	2.7	23
109	The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 47, 1281-5	4	23
108	A review and interpretation of cytogenetic abnormalities identified in Hodgkin's disease. <i>Hematological Oncology</i> , 1988 , 6, 271-4	1.3	23
107	Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2017 , 178, 2504-2516	4.5	22
106	Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®)) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2013 , 162, 631-8	4.5	22
105	Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2012 , 53, 50-6	1.9	22
104	Front-line management of diffuse large B cell lymphoma. <i>Current Opinion in Oncology</i> , 2010 , 22, 642-5	4.2	22
103	Unbalanced expression of Fas and CD40 in mantle cell lymphoma. <i>British Journal of Haematology</i> , 1998 , 103, 217-9	4.5	22
102	Trimetrexate in relapsed T-cell lymphoma with skin involvement. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2876-80	2.2	22
101	Primary mediastinal large cell lymphoma. <i>Hematological Oncology</i> , 1994 , 12, 175-84	1.3	22

100	Human central nervous system pharmacology of pentamethylmelamine and its metabolites. <i>Journal of Neuro-Oncology</i> , 1983 , 1, 357-64	4.8	22
99	Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β_2 -microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. <i>British Journal of Haematology</i> , 2016 , 175, 290-299	4.5	21
98	Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. <i>Cancer</i> , 2001 , 91, 2440-2446	6.4	21
97	The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage IA through IIB Hodgkin's disease: preliminary results. <i>International Journal of Radiation Oncology Biology Physics</i> , 1988 , 14, 683-92	4	21
96	Primary non-Hodgkin lymphoma of the small bowel. <i>Radiology</i> , 1999 , 211, 183-7	20.5	20
95	Subdiaphragmatic stage I & II Hodgkin's disease: long-term follow-up and prognostic factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998 , 41, 1047-56	4	19
94	Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. <i>Cancer</i> , 2005 , 104, 345-53	6.4	19
93	Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers. <i>Blood</i> , 2001 , 98, 2877-8	2.2	19
92	Mucosa-associated lymphoid tissue lymphoma with initial supradiaphragmatic presentation: natural history and patterns of disease progression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 48, 399-403	4	19
91	Tumor necrosis factor-alpha and interferon-gamma, but not HTLV-I tax, are likely factors in the epidermotropism of cutaneous T-cell lymphoma via induction of interferon-inducible protein-10. <i>Leukemia and Lymphoma</i> , 1998 , 29, 315-28	1.9	19
90	Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy. <i>Cancer</i> , 2003 , 98, 1021-8	6.4	18
89	Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?. <i>Annals of Oncology</i> , 2002 , 13, 318-22	10.3	18
88	Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 1999 , 32, 279-88	1.9	18
87	Apoptosis and the Bcl-2 gene family -- patterns of expression and prognostic value in stage I and II follicular center lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 44, 19-29	4	18
86	Chromosomal abnormalities in lymphoma and their correlations with nucleic acid flow cytometry. <i>Cancer Genetics and Cytogenetics</i> , 1986 , 21, 99-106		18
85	Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm?. <i>Journal of Clinical Oncology</i> , 2013 , 31, 14-6	2.2	17
84	Evaluation of Breast Imaging Reporting and Data System Category 3 mammograms and the use of stereotactic vacuum-assisted breast biopsy in a nonacademic community practice. <i>Cancer</i> , 2004 , 100, 710-4	6.4	17
83	Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. <i>Leukemia and Lymphoma</i> , 1995 , 17, 473-7	1.9	17

82	Polysomy of chromosome 12 in 60 patients with non-Hodgkin's lymphoma assessed by fluorescence in situ hybridization: differences between follicular and diffuse large cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 1994 , 9, 161-7	5	17
81	Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic units. <i>American Journal of Medicine</i> , 1984 , 76, 405-12	2.4	17
80	Intensive induction chemotherapy of extensive small cell bronchogenic carcinoma in protected environment--prophylactic antibiotic units. A preliminary report. <i>International Journal of Radiation Oncology Biology Physics</i> , 1980 , 6, 1087-92	4	17
79	Importance of esophagogastroduodenoscopy in the evaluation of non-gastrointestinal mucosa-associated lymphoid tissue lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2003 , 9, 321-4	2.2	16
78	Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. <i>Leukemia and Lymphoma</i> , 1995 , 18, 87-92	1.9	16
77	Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in-situ hybridization. <i>British Journal of Haematology</i> , 1997 , 98, 913-21	4.5	15
76	Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 57, 316-20	4	14
75	Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 50, 971-7	4	14
74	Ventricular fibrillation following AMSA. Uncomplicated retreatment following correction of hypokalemia. <i>Cancer</i> , 1983 , 52, 557-8	6.4	14
73	Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007 , 30, 163-71	2.7	13
72	Comparison of lymphangiograms and gallium scans in the non-Hodgkin's lymphomas. <i>Cancer</i> , 1977 , 39, 85-8	6.4	13
71	High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. <i>British Journal of Haematology</i> , 2017 , 177, 263-270	4.5	12
70	Non-Hodgkin's lymphoma: the old and the new. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11 Suppl 1, S87-90	2	12
69	Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 1997 , 26, 77-82	1.9	12
68	Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later?. <i>Puerto Rico Health Sciences Journal</i> , 2010 , 29, 215-7	0.5	12
67	Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. <i>British Journal of Haematology</i> , 2014 , 166, 920-8	4.5	11
66	Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations. <i>Leukemia and Lymphoma</i> , 1997 , 27, 517-21	1.9	11
65	Stage III follicular lymphoma: long-term follow-up and patterns of failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 57, 748-54	4	11

64	Quantitative real-time polymerase chain reaction for detection of circulating cells with t(14;18) in volunteer blood donors and patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1589-98	1.9	11
63	16-year experience at M. D. Anderson Cancer Center with primary Ki-1 (CD30) antigen expression and anaplastic morphology in adult patients with diffuse large cell lymphoma. <i>Leukemia and Lymphoma</i> , 1995 , 20, 97-102	1.9	11
62	How important is whole brain radiotherapy for treatment of primary CNS lymphoma?. <i>Lancet Oncology, The</i> , 2010 , 11, 1011-2	21.7	10
61	Monosomy 21, partial duplication of chromosome 11, and structural abnormality of chromosome 1q21 in a case of lymphoma developing in a transplant recipient: characteristic abnormalities of secondary lymphoma?. <i>Cancer Genetics and Cytogenetics</i> , 1987 , 24, 7-10		10
60	Effective combination chemotherapy of adult malignant histiocytosis (histiocytic medullary reticulosis). <i>Medical and Pediatric Oncology</i> , 1978 , 4, 29-34		10
59	Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 1996 , 24, 103-10	1.9	9
58	Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: prognostic factors for survival and freedom from progression. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997 , 38, 593-9	4	9
57	The significance of molecular response of follicular lymphoma to central lymphatic irradiation as measured by polymerase chain reaction for t(14;18)(q32;q21). <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 49, 727-32	4	9
56	Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1769-75	1.9	9
55	Use of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients). <i>Human Gene Therapy</i> , 1993 , 4, 821-34	4.8	9
54	Simultaneous presentation of hairy cell leukemia and follicular small cleaved cell lymphoma in a patient with previous diagnosis of renal cell carcinoma. <i>Hematological Oncology</i> , 1995 , 13, 63-7	1.3	9
53	Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1998 , 103, 678-83	4.5	8
52	High incidence of monosomy 18 in lymphoid malignancies that have bone marrow and peripheral blood involvement. <i>Cancer Genetics and Cytogenetics</i> , 1994 , 77, 39-44		8
51	Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 550-557	2	7
50	Study of the natural history of immunoblastic lymphadenopathy and atypical immunoproliferative disorders. <i>Cancer Investigation</i> , 1983 , 1, 293-9	2.1	7
49	The hematologic malignancies. Leukemia, lymphoma, and myeloma. <i>Cancer</i> , 1984 , 54, 2741-50	6.4	7
48	Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2008 , 112, 833-833	2.2	7
47	Correlation of Bcl-2 Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma. <i>Blood</i> , 1999 , 93, 3081-3087	2.2	7

46	Recent advances in the management of mantle cell lymphoma. <i>Current Opinion in Oncology</i> , 2013 , 25, 716-21	4.2	6
45	Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma. <i>Cancer</i> , 2002 , 94, 601-5	6.4	6
44	A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, 188-93	4	6
43	Chromosome X numerical abnormalities in patients with non-Hodgkin's lymphoma. A study of 59 patients using fluorescence in situ hybridization. <i>Cancer Genetics and Cytogenetics</i> , 1995 , 82, 23-9		6
42	Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease. <i>Leukemia and Lymphoma</i> , 1993 , 9, 71-7	1.9	6
41	Mantle Cell Lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant?. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2509-2511	1.9	5
40	Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1818-21	1.9	5
39	Establishment and characterization of a new mantle cell lymphoma cell line M-1. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1255-60	1.9	5
38	What constitutes a "cure" in lymphoma?. <i>Leukemia and Lymphoma</i> , 1993 , 11, 161-3	1.9	5
37	Lymphomatous presentation of CD4+/CD8+ HTLV-1-related adult T-cell leukemia/lymphoma in an Iranian woman. <i>Leukemia and Lymphoma</i> , 1994 , 12, 471-6	1.9	5
36	Philadelphia chromosome without breakpoint cluster region rearrangement in a case of Lennert's lymphoma of suppressor phenotype. <i>Hematological Oncology</i> , 1989 , 7, 189-94	1.3	5
35	Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin lymphoma: a prognostic factor comparison of two regimens. <i>Medical and Pediatric Oncology</i> , 1978 , 4, 321-31		5
34	Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, e275-e277	2	4
33	Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab. <i>Journal of Clinical Oncology</i> , 2011 , 29, e658-60	2.2	4
32	Hematologic recovery after central lymphatic irradiation for patients with stage I-III follicular lymphoma. <i>Cancer</i> , 2001 , 92, 1074-9	6.4	4
31	Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement. <i>Annals of Oncology</i> , 2002 , 13, 1290-9	10.3	4
30	Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. <i>Investigational New Drugs</i> , 1999 , 17, 187-92	4.3	4
29	Results of Upfront Therapy for Marginal Zone Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 879-883	2	3

28	Incidence and Risk Factors for Developing Herpes Zoster Among a Cohort of Patients Diagnosed With Lymphoma at a Community Cancer Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e153-e158	2	3
27	Rituximab in DLBCL: 6 years on. <i>Lancet Oncology, The</i> , 2011 , 12, 984-5	21.7	3
26	Therapeutic concepts in mantle cell lymphoma. <i>European Journal of Haematology</i> , 2010 , 85, 371-86	3.8	3
25	Human B cell lymphomas: in vitro and in vivo studies on growth factors and cell growth. <i>Leukemia and Lymphoma</i> , 1993 , 10 Suppl, 51-6	1.9	3
24	HLA class II antigen associated invariant chain gene expression in malignant lymphoma. <i>British Journal of Haematology</i> , 1987 , 67, 413-7	4.5	3
23	Check this checkpoint inhibitor in lymphoma. <i>Blood</i> , 2017 , 130, 234-235	2.2	2
22	Pixantrone: a new agent for relapsed aggressive lymphomas. <i>Lancet Oncology, The</i> , 2012 , 13, 654-6	21.7	2
21	Endocrine characterization of primary mediastinal lymphoma. <i>Leukemia and Lymphoma</i> , 1996 , 23, 613-5	1.9	2
20	Hodgkin's disease: correlation of clinical characteristics with probabilities for negative lymphangiogram vs. negative laparotomy findings in patients with Stage I supradiaphragmatic presentations vs. those in patients with Stage II. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998 , 40, 377-86	4	2
19	Dose dense CHOP: when more is not always better!. <i>Leukemia and Lymphoma</i> , 2007 , 48, 845-6	1.9	2
18	The Baseline PET SUV Correlates Better with Clinical Outcome Than the Post-Therapy PET Scan in Previously Untreated Patients with Histologically Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2008 , 112, 3588-3588	2.2	2
17	A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 776-783	2	1
16	Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1929-33	1.9	1
15	New developments in the field of diffuse large cell lymphoma. <i>Hematology</i> , 2012 , 17 Suppl 1, S98-100	2.2	1
14	Historical Perspective on the Treatment Challenges of Low-Grade Non-Hodgkin Lymphoma. <i>Seminars in Hematology</i> , 2007 , 44, S2-S6	4	1
13	Salvage central lymphatic irradiation in follicular lymphomas following failure of chemotherapy: a feasibility study. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 45, 1207-12	4	1
12	A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. <i>Investigational New Drugs</i> , 1994 , 12, 217-22	4.3	1
11	Managing Indolent Lymphomas in Relapse. <i>Hematology American Society of Hematology Education Program</i> , 2000 , 2000, 166-179	3.1	1

10	Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. <i>European Journal of Haematology</i> , 2020 , 104, 400-408	3.8	1
9	Single-Arm, Open-Label Phase 2 Trial of Preemptive Methylprednisolone to Avert Progression to Respiratory Failure in High-Risk Patients with COVID-19 2021 ,		1
8	Reply to I.E. Haines. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1798	2.2	
7	Molecular response of follicular lymphoma to cyclophosphamide, doxorubicin, vincristine, prednisone C(H)OP or COP-based therapy as measured by polymerase chain reaction evidence of translocation (14;18)(q32;q21). <i>Cancer Journal (Sudbury, Mass)</i> , 2004 , 10, 49-53	2.2	
6	Frontline Management of Intermediate Grade Lymphomas at M. D. Anderson Hospital. <i>Leukemia and Lymphoma</i> , 1992 , 7, 70-71	1.9	
5	Benign fibrous histiocytoma in Hodgkin's disease. <i>Cancer Investigation</i> , 1984 , 2, 347-50	2.1	
4	Rectal adenocarcinoma: proposal for a model based on pretreatment prognostic factors. <i>Puerto Rico Health Sciences Journal</i> , 2012 , 31, 52-8	0.5	
3	Managing Indolent Lymphomas in Relapse. <i>Hematology American Society of Hematology Education Program</i> , 2000 , 2000, 166-179	3.1	
2	T-Cell Rich B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 1997 , 21, 499-500	6.7	
1	Gastric MALT Lymphoma with Biclonal Gammopathy and Bone Marrow Involvement Mimicking Multiple Myeloma. <i>Puerto Rico Health Sciences Journal</i> , 2020 , 39, 275-277	0.5	